Independent UK Compound Guide
Tirzepatide
Independent information on how Tirzepatide works, what clinical research shows, common side effects, injection frequency and its relationship to Mounjaro®.
Slim Shots is an independent educational resource. Tirzepatide is a prescription-only medicine in the UK. This page does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Tirzepatide Explained
What Is Tirzepatide?
Tirzepatide is a medicine that acts on two hormone pathways: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is the active ingredient in the branded medicine Mounjaro®.
These pathways are involved in appetite, fullness and blood-glucose regulation. Depending on the product, an individual's clinical circumstances and a prescriber's assessment, Tirzepatide may be used in relation to type 2 diabetes or weight management.
In the UK, licensed Tirzepatide medicines are prescription-only. Suitability depends on an individual's health, medical history, current medicines and treatment goals.
Mechanism of Action
How Does Tirzepatide Work?
Tirzepatide is sometimes described as a dual agonist because it acts on both GIP and GLP-1 receptors.
Appetite and Fullness
Activity at GLP-1 and GIP receptors can affect appetite and help some people feel full after eating less food.
Digestive Effects
Tirzepatide can affect gastric emptying, which may contribute to longer-lasting feelings of fullness and can also cause digestive side effects for some people.
Blood-Glucose Regulation
The GIP and GLP-1 pathways are also involved in insulin and glucagon responses, which is relevant to Tirzepatide's role in type 2 diabetes treatment.
Product Imagery
Tirzepatide Vial
Tirzepatide products can differ by presentation, dose, delivery method and prescribing instructions. Always follow the information supplied with the specific product prescribed or provided to you.
Tirzepatide
Product presentation
Clinical Research
How Much Weight Can You Lose With Tirzepatide?
Weight-loss outcomes differ between individuals. Results may be affected by baseline weight, dose, treatment duration, nutrition, activity, tolerability, health conditions and other medicines.
In the SURMOUNT-1 clinical trial, adults with obesity or overweight without diabetes receiving Tirzepatide 15 mg alongside lifestyle intervention had an average body-weight reduction of approximately 20.9% over 72 weeks.
Clinical-trial averages are not guarantees of individual outcomes. A qualified prescriber can assess whether a treatment is appropriate and monitor progress.
SURMOUNT-1 Clinical Trial
20.9%
Average body-weight reduction over 72 weeks
Reported for participants receiving Tirzepatide 15 mg alongside lifestyle intervention. Individual results can vary substantially.
Product Context
Tirzepatide and Mounjaro®
Tirzepatide is the active ingredient in Mounjaro®. The medicine, prescribing assessment, dose schedule and product instructions remain important parts of using any prescribed treatment safely.
| Topic | Tirzepatide | Important Context |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide is the active ingredient in Mounjaro®. |
| Hormone pathways | GIP and GLP-1 receptor activity. | Tirzepatide differs from medicines that act on the GLP-1 pathway alone. |
| Dosing and delivery | Product-specific and prescribed individually. | Follow directions from a clinician, pharmacist and the product information for the medicine supplied. |
| Suitability | Assessed individually. | A qualified healthcare professional should consider medical history, current medicines, treatment goals and potential risks. |
Tirzepatide FAQs
Frequently Asked Questions About Tirzepatide
Clear answers to common questions about Tirzepatide, including Mounjaro®, side effects, injections, results and stopping treatment.
What is Tirzepatide?
Tirzepatide is a medicine that acts on both GIP and GLP-1 receptors. It is the active ingredient in Mounjaro®. In the UK, licensed Tirzepatide medicines are prescription-only.
Is Tirzepatide the same as Mounjaro®?
Tirzepatide is the active ingredient in Mounjaro®. A medicine's delivery device, instructions, licensed use, prescribing process and dose schedule are still specific to the product and clinical decision involved.
How does Tirzepatide work for weight loss?
Tirzepatide acts on GIP and GLP-1 pathways that are involved in appetite, fullness and blood-glucose regulation. It can reduce appetite and affect how full some people feel after eating. For eligible people, it may be used alongside nutrition, activity and behavioural changes as part of a wider treatment plan.
How much weight can you lose with Tirzepatide?
Results vary between people. In the SURMOUNT-1 clinical trial, participants receiving Tirzepatide 15 mg alongside lifestyle intervention had an average body-weight reduction of approximately 20.9% after 72 weeks. This is a clinical-trial average, not a guaranteed individual result.
How often is Tirzepatide injected?
Injectable Tirzepatide is generally administered once weekly. The exact dose schedule and injection instructions depend on the prescribed product. A clinician or pharmacist should explain injection technique, injection sites and site rotation.
What are the common side effects of Tirzepatide?
Common side effects can include nausea, vomiting, diarrhoea, constipation, stomach pain, indigestion, reduced appetite, headache and tiredness. Digestive side effects can be more noticeable when treatment begins or after a dose change.
Are there serious Tirzepatide side effects to be aware of?
Serious side effects are less common but can occur. Seek urgent medical advice for severe or persistent abdominal pain, signs of a serious allergic reaction, repeated vomiting or diarrhoea causing dehydration, or sudden changes in vision. Discuss your medical history and medicines with a prescriber before treatment.
What happens when you stop taking Tirzepatide?
The effects on appetite and fullness reduce after treatment stops. Weight regain can occur, especially without continued nutrition, activity and behavioural support. Speak to your prescriber before stopping treatment, particularly if Tirzepatide is being used for type 2 diabetes.
Is Tirzepatide stronger than Semaglutide?
Tirzepatide and Semaglutide act differently: Tirzepatide targets both GIP and GLP-1 receptors, while Semaglutide acts on the GLP-1 receptor. Research findings, dose schedules and clinical suitability should not be treated as a direct guarantee that one medicine will be more appropriate for every individual.
Do you need a prescription for Tirzepatide in the UK?
Yes. Licensed Tirzepatide medicines are prescription-only in the UK. Appropriate assessment, prescribing and monitoring should be provided by a qualified healthcare professional.
Safety and Suitability
Tirzepatide Is Not Suitable for Everyone
Before prescribing Tirzepatide, a healthcare professional should consider medical history, existing conditions, current medicines, previous side effects and pregnancy plans.
Only use medicines obtained through an appropriate regulated route. If you experience a suspected side effect, speak to a healthcare professional. In the UK, suspected side effects can also be reported through the MHRA Yellow Card scheme.
Keep Exploring
Related Tirzepatide Information
Explore more independent information on Tirzepatide, Semaglutide and wider GLP-1 compound topics.
Tirzepatide vs Mounjaro®
Understand the relationship between Tirzepatide and the branded medicine Mounjaro®.
READ THE COMPARISON →Semaglutide Guide
Learn about Semaglutide, a GLP-1 receptor agonist and the active ingredient in Wegovy® and Ozempic®.
EXPLORE SEMAGLUTIDE →Expert Advice Hub
Browse science-led information on GLP-1 compounds, research and commonly asked questions.
EXPLORE EXPERT ADVICE →GLP-1 Information
Read general educational information about GLP-1 compounds and product-specific instructions.
READ THE GUIDE →General GLP-1 FAQs
Find answers to broader questions about GLP-1 compounds, research and information covered by Slim Shots.
VIEW ALL FAQS →Latest Articles
Read the latest Slim Shots educational articles about Tirzepatide, GLP-1 medicines and compound comparisons.
VISIT THE BLOG →Further Reading
Tirzepatide Information Sources
- Clinical weight-loss evidence: Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1 clinical trial.
- UK medicine information: NHS medicine guidance and the official product information supplied with the prescribed medicine.
- Side effects and safety information: UK Medicines and Healthcare products Regulatory Agency and the British National Formulary.
Tirzepatide Information
View Tirzepatide Options
Review available Tirzepatide information and understand the importance of professional medical assessment before making a health-related decision.
VIEW TIRZEPATIDE OPTIONS →